Liver cirrhosis has long been considered irreversible. Once scar tissue forms, the prevailing wisdom was you can only slow it down. That thinking is shifting, and a 2026 Phase I trial just added significant weight to the argument.<\/p>\n
The trial tested allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) administered directly into the hepatic artery. Twelve patients with decompensated liver cirrhosis (Child-Pugh B and C) received three infusions over six weeks.<\/p>\n
<\/p>\n
Why not just inject MSCs intravenously? When given through a peripheral vein, most MSCs get trapped in the lungs \u2014 the “pulmonary first-pass effect.” By threading a catheter into the hepatic artery, cells go directly to the liver, resulting in 8x higher engraftment.<\/p>\n
The results were striking:<\/p>\n
One patient \u2014 a 58-year-old male with hepatitis B-related cirrhosis \u2014 regressed from Child-Pugh C to Child-Pugh A. His ascites resolved completely and he was removed from the transplant waitlist.<\/p>\n
UC-MSCs are more primitive than bone marrow-derived MSCs, with higher proliferation capacity and stronger immunosuppressive properties. They secrete more hepatocyte growth factor (HGF), which drives liver regeneration. Each infusion contained 1×10^6 cells per kilogram of body weight.<\/p>\n
Liver cirrhosis is highly prevalent in Southeast Asia \u2014 driven by hepatitis B, alcohol, and increasingly NAFLD. A therapy that reverses fibrosis would transform hepatology. Several Phase II trials are recruiting across Asia now.<\/p>\n
Li, Y., et al. (2026). Safety and preliminary efficacy of allogeneic umbilical cord-derived mesenchymal stem cells administered via the hepatic artery in patients with liver cirrhosis: A phase I open-label trial. Stem Cell Research & Therapy<\/em>, 17(1).<\/p>\n